section name header

Evidence summaries

Azathioprine for Primary Biliary Cirrhosis

Azathioprine appears not to be effective for patients with primary biliary cirrhosis Level of evidence: "B"

A Cochrane review [Abstract] 1 included 2 studies with a total of 293 subjects. Only one of the trials was regarded as having low bias risk. Azathioprine did not significantly decrease mortality (RR 0.80, 95% CI 0.49 to 1.31, 2 trials). Azathioprine did not improve pruritus at one-year intervention (RR 0.71, 95% CI 0.28 to 1.84, 1 trial), cirrhosis development, or quality of life. Patients given azathioprine experienced significantly more adverse events than patients given no intervention or placebo (RR 2.44, 95% CI 1.14 to 5.20, 2 trials). The common adverse events were rash, severe diarrhoea, and bone marrow depression.

Comment: The quality of evidence is downgraded by imprecise results (few patients and wide confidence intervals).

References

  • Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev 2007 Jul 18;(3):CD006000. [PubMed]

Primary/Secondary Keywords